NCT06355895 Liver Volume Variation Effect on SBRT Planning and Delivery for Upper Abdominal Malignancies
| NCT ID | NCT06355895 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of Pittsburgh |
| Condition | Upper Abdominal Malignancies |
| Study Type | INTERVENTIONAL |
| Enrollment | 17 participants |
| Start Date | 2024-05-16 |
| Primary Completion | 2028-03-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 17 participants in total. It began in 2024-05-16 with a primary completion date of 2028-03-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Standard planning constraints for liver SBRT incorporate strict dose-volume limits for normal liver parenchyma to minimize the risk of radiation-induced liver disease. The presence of diurnal and fasting/fed variations in liver volume therefore carry substantial potential for introducing errors into estimates of dose-volume distribution within normal liver tissue, as well as affecting day-to-day setup fidelity and organ alignment for treatment. This prospective study will examine how diurnal and fast-fed variations in liver volume affect treatment planning for abdominal SBRT.
Eligibility Criteria
Inclusion Criteria: • Have primary upper abdominal (pancreatic, bile duct, liver) cancer or upper abdominal metastases (liver, adrenal, upper abdominal lymph nodes) planned to undergo SBRT. Exclusion Criteria: * Had prior Radiation Therapy to the liver * Contraindication to receipt of iodinated IV contrast for CT (such as renal insufficiency or allergy that cannot be overcome by premedication) * Pregnancy/lactation OR woman of childbearing potential who is unable or unwilling to use adequate contraception during Radiation Therapy. * Inability to fast.
Contact & Investigator
Susannah Ellsworth, MD
PRINCIPAL INVESTIGATOR
UPMC Hillman Cancer Center
Frequently Asked Questions
Who can join the NCT06355895 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Upper Abdominal Malignancies. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06355895 currently recruiting?
Yes, NCT06355895 is actively recruiting participants. Contact the research team at albesl@upmc.edu for enrollment information.
Where is the NCT06355895 trial being conducted?
This trial is being conducted at Pittsburgh, United States.
Who is sponsoring the NCT06355895 clinical trial?
NCT06355895 is sponsored by University of Pittsburgh. The principal investigator is Susannah Ellsworth, MD at UPMC Hillman Cancer Center. The trial plans to enroll 17 participants.